Stock IPN IPSEN
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 11:38:02 2024-04-26 am EDT 		5-day change 1st Jan Change
113 EUR +0.62% Intraday chart for Ipsen +4.24% +4.73%
Apr. 24 IPSEN : Better-than-expected Q1; guidance unchanged Alphavalue
Apr. 24 Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,560 5,609 6,621 8,279 8,912 9,334 - -
Enterprise Value (EV) 1 7,675 6,139 6,758 7,894 8,847 8,749 8,160 7,404
P/E ratio -130 x 10.3 x 10.4 x 12.9 x 14 x 14.6 x 13.1 x 11.9 x
Yield 1.27% 1.47% 1.49% 1.19% 1.11% 1.05% 1.07% 1.05%
Capitalization / Revenue 2.55 x 2.16 x 2.31 x 2.74 x 2.85 x 2.71 x 2.53 x 2.39 x
EV / Revenue 2.98 x 2.37 x 2.36 x 2.61 x 2.83 x 2.54 x 2.22 x 1.89 x
EV / EBITDA 8.13 x 6.28 x 5.8 x 5.86 x 10 x 7.23 x 6.44 x 5.5 x
EV / FCF 15.9 x 8.9 x 8.31 x 9.02 x 12.4 x 14.3 x 11.1 x 8.05 x
FCF Yield 6.3% 11.2% 12% 11.1% 8.04% 6.97% 9.01% 12.4%
Price to Book 3.78 x 2.67 x 2.42 x - 2.36 x 2.2 x 1.91 x 1.66 x
Nbr of stocks (in thousands) 83,035 82,601 82,243 82,380 82,599 82,599 - -
Reference price 2 79.00 67.90 80.50 100.5 107.9 113.0 113.0 113.0
Announcement Date 2/13/20 2/11/21 2/11/22 2/9/23 2/8/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,576 2,592 2,869 3,025 3,128 3,445 3,683 3,912
EBITDA 1 943.8 977.5 1,166 1,348 881.4 1,210 1,267 1,347
EBIT 1 782.6 829.3 1,011 1,115 1,001 1,014 1,113 1,199
Operating Margin 30.38% 32% 35.25% 36.87% 32.01% 29.44% 30.2% 30.64%
Earnings before Tax (EBT) 1 -38.5 528.8 814.6 705.9 761.5 763.6 904 1,005
Net income 1 -50.7 548 646.6 647.5 647.2 644.6 717.9 766.8
Net margin -1.97% 21.15% 22.54% 21.4% 20.69% 18.71% 19.49% 19.6%
EPS 2 -0.6100 6.570 7.760 7.810 7.730 7.754 8.606 9.482
Free Cash Flow 1 483.2 689.9 813.2 874.8 710.9 609.8 734.9 919.9
FCF margin 18.76% 26.62% 28.35% 28.92% 22.73% 17.7% 19.95% 23.51%
FCF Conversion (EBITDA) 51.2% 70.58% 69.74% 64.88% 80.66% 50.41% 57.98% 68.31%
FCF Conversion (Net income) - 125.89% 125.77% 135.1% 109.84% 94.61% 102.36% 119.98%
Dividend per Share 2 1.000 1.000 1.200 1.200 1.200 1.184 1.206 1.186
Announcement Date 2/13/20 2/11/21 2/11/22 2/9/23 2/8/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1
Net sales 1 1,347 1,268 1,323 1,350 727.4 791.2 1,519 687.9 745.8 1,434 774.8 816.4 1,591 741.9 794.7 1,537 772.4 818.5 1,591 822.4
EBITDA - - - - 320.9 320.9 - - - - - - - - - - - - - -
EBIT 395.1 410.2 419.1 479.8 - - 531.5 - - 568 - - 547.4 - - 523.2 - - 477.8 -
Operating Margin 29.34% 32.34% 31.67% 35.53% - - 35% - - 39.62% - - 34.4% - - 34.05% - - 30.03% -
Earnings before Tax (EBT) -321.4 270.1 258.7 400.9 - - 413.7 - - - - - - - - - - - - -
Net income -271.3 222.7 325.3 304 - - 342.6 - - - - - 253.2 - - - - - - -
Net margin -20.15% 17.56% 24.58% 22.51% - - 22.56% - - - - - 15.91% - - - - - - -
EPS -3.250 2.660 3.910 3.640 - - 4.120 - - - - - 3.070 - - 2.350 - - 5.380 -
Dividend per Share - - - - - - - - - - - - 1.200 - - - - - - -
Announcement Date 2/13/20 7/30/20 2/11/21 7/29/21 11/11/21 2/11/22 2/11/22 4/27/22 7/28/22 7/28/22 10/27/22 2/9/23 2/9/23 4/27/23 7/27/23 7/27/23 10/26/23 2/8/24 2/8/24 4/24/24
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,116 531 138 - - - - -
Net Cash position 1 - - - 385 65.1 585 1,173 1,930
Leverage (Debt/EBITDA) 1.182 x 0.5427 x 0.1182 x - - - - -
Free Cash Flow 1 483 690 813 875 711 610 735 920
ROE (net income / shareholders' equity) 31.3% 28.3% 26.5% 28.7% 21.4% 17.6% 16.7% 15.7%
ROA (Net income/ Total Assets) - 12.7% 13.9% 16.5% 12.8% 9.66% 10.5% 10.1%
Assets 1 - 4,312 4,660 3,933 5,046 6,676 6,813 7,607
Book Value Per Share 2 20.90 25.40 33.30 - 45.60 51.40 59.30 68.10
Cash Flow per Share 2 7.550 9.250 10.90 11.70 10.40 9.670 11.30 14.20
Capex 1 145 81.4 96 96.6 116 121 116 136
Capex / Sales 5.61% 3.14% 3.35% 3.19% 3.72% 3.52% 3.15% 3.48%
Announcement Date 2/13/20 2/11/21 2/11/22 2/9/23 2/8/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Ipsen

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
113 EUR
Average target price
125.1 EUR
Spread / Average Target
+10.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
IPSEN Stock Ipsen
+4.73% 9.96B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IPN Stock
  4. Financials Ipsen